Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc. is experiencing substantial growth, marked by a remarkable 98% increase in revenue for the third quarter, reaching $13.1 million, driven primarily by a significant rise in surgeon utilization and an expanding user base of over 220 surgeons. The company's robust performance is further underscored by a year-over-year growth rate of approximately 70% in surgeon customers and a stable productivity metric of 1.9 units per surgeon, indicating strong adoption of its Aprevo technology platform in the $13.4 billion U.S. lumbar fusion market. Additionally, the company maintains an impressive gross margin of 75.9%, boosted by lower contract manufacturing costs and a reduced inventory reserve, positioning Carlsmed favorably for continued revenue expansion and a compound annual growth rate exceeding 50% from 2024 to 2028.

Carlsmed Inc. faces a challenging outlook due to projected cervical revenue for FY26, estimated at $2.9 million, which falls short of the $3.4 million anticipated by analysts. Key risks contributing to this negative perspective include a slower-than-expected adoption of the Aprevo technology by new surgeons, a weaker overall growth rate in the spine market, and potential for higher operating expenses than previously modeled. Additionally, market competition from larger spine players and reimbursement changes that may negatively impact hospital economics further complicate Carlsmed’s ability to gain market share and enhance pricing power for its products.